FDAAA实施前后支持FDA批准神经精神药物的临床试验注册、结果报告与发表偏倚
该回顾性队列研究纳入2005至2014年支持FDA批准37种神经精神药物的142项疗效试验,按FDAAA实施前后分组。FDAAA后试验注册率(100% vs 64%)和结果报告率(100% vs 10%)显著提高,发表偏倚程度显著降低。
要点
- FDAAA实施后神经精神药物试验注册率和结果报告率均达100%。
- FDAAA前阳性试验更易发表且无误导性解读,发表偏倚显著。
- FDAAA后阳性与非阳性试验发表可能性无差异,发表偏倚降低。
核心结论
- FDAAA实施后,支持FDA批准神经精神药物的试验注册和结果报告比例显著提高,发表偏倚程度显著降低。
研究设计与样本
- 回顾性队列研究,纳入2005至2014年支持FDA批准37种神经精神药物的142项疗效试验,其中FDAAA前101项、后41项。
主要发现
- FDAAA后试验注册率显著高于FDAAA前(100% vs 64%;p < 0.001)。
- FDAAA后结果报告率显著高于FDAAA前(100% vs 10%;p < 0.001)。
- FDAAA前阳性试验更易发表(RR = 1.52;95% CI = 1.17-1.99;p = 0.002)且更易无误导性解读发表(RR = 2.47;95% CI = 1.57-3.73;p < 0.001)。
- FDAAA后阳性与非阳性试验发表可能性相同(RR = 1;95% CI = 1-1;p = NA),无误导性解读发表可能性无差异(RR = 1.20;95% CI = 0.84-1.72;p = 0.30)。
- FDAAA前较FDAAA后发表偏倚更大(RRR = 1.52;95% CI = 1.16-1.99;p = 0.002),无误导性解读发表偏倚更大(RRR = 2.06;95% CI = 1.17-3.61;p = 0.01)。
临床怎么用
- 在评估神经精神药物证据时,应优先核查试验注册与结果报告情况,关注FDAAA前的发表偏倚风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mandatory trial registration, and later results reporting, were proposed to mitigate selective clinical trial publication and outcome reporting. The Food and Drug Administration (FDA) Amendments Act (FDAAA) was enacted by Congress on September 27, 2007, requiring the registration of all non-phase I clinical trials involving FDA-regulated medical interventions and results reporting for approved drugs. The association between FDAAA enactment and the registration, results reporting, and publication bias of neuropsychiatric trials has not been studied. METHODS: We conducted a retrospective cohort study of all efficacy trials supporting FDA new drug approvals between 2005 to 2014 for neuropsychiatric indications. Trials were categorized as pre- or post-FDAAA based on initiation and/or completion dates. The main outcomes were the proportions of trials registered and reporting results in ClinicalTrials.gov, and the degree of publication bias, estimated using the relative risks pre- and post-FDAAA of both the publication of positive vs non-positive trials, as well as of publication of positive vs non-positive trials without misleading interpretations. Registration and results reporting proportions were compared pre- and post-FDAAA using the two-tailed Fisher exact test, and the degrees of publication bias were compared by calculating the ratio of relative risks (RRR) for each period. RESULTS: The FDA approved 37 new drugs for neuropsychiatric indications between 2005 and 2014 on the basis of 142 efficacy trials, of which 101 were pre-FDAAA and 41 post-FDAAA. Post-FDAAA trials were significantly more likely to be registered (100% vs 64%; p < 0.001) and report results (100% vs 10%; p < 0.001) than pre-FDAAA trials. Pre-FDAAA, positive trials were more likely to be published (relative risk [RR] = 1.52; 95% confidence interval [CI] = 1.17-1.99; p = 0.002) and published without misleading interpretations (RR = 2.47; CI = 1.57-3.73; p < 0.001) than those with non-positive results. In contrast, post-FDAAA positive trials were equally likely to have been published (RR = 1; CI = 1-1, p = NA) and published without misleading interpretations (RR = 1.20; CI = 0.84-1.72; p = 0.30). The likelihood of publication bias pre-FDAAA vs post-FDAAA was greater for positive vs non-positive trials (RRR = 1.52; CI = 1.16-1.99; p = 0.002) and for publication without misleading interpretations (RRR = 2.06, CI = 1.17-3.61, p = 0.01). CONCLUSIONS: The enactment of FDAAA was followed by significantly higher proportions of trials that were registered and reporting results on ClinicalTrials.gov and significantly lower degrees of publication bias among trials supporting recent FDA approval of drugs for neuropsychiatric indications.
引用
- Zou CX, Becker JE, Phillips AT, et al. Registration, results reporting, and publication bias of clinical trials supporting FDA approval of neuropsychiatric drugs before and after FDAAA: a retrospective cohort study. Trials. 2018. PMID: 30352601. doi:10.1186/s13063-018-2957-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。